CRISPR Therapeutics
Agent44Agent Readiness: 44/100. Above median. Measured by StartupHub.ai. Median 41.Trust67Data Trust: 67/100. Above median. Measured by StartupHub.ai. Median 61.Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.
About
CRISPR Therapeutics is a Swiss-American biotechnology company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines for serious diseases. They develop cures for genetic diseases by precisely modifying DNA, with a diverse portfolio including treatments for hemoglobinopathies, oncology, and regenerative medicine. Their lead program, exagamglogene autotemcel (exa-cel), has received regulatory approval in several countries for sickle cell disease and transfusion-dependent beta thalassemia.
Listed competitors
A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
A biotechnology company developing precision genetic medicines through base editing technology to treat a broad range of diseases.
A clinical-stage genome editing company developing novel therapies using CRISPR/Cas9 technology for severe diseases.
Also in this space
Scalable, one-time curative in-vivo gene editing therapies.
Shares Biotechnology, Pharmaceuticals
Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.
Shares Biotechnology, Gene Editing
A clinical-stage biotechnology company developing in vivo gene editing therapies.
Shares Biotechnology, Pharmaceuticals
Developing disease-responsive advanced therapies through programmable gene control technology.
Shares Biotechnology, Therapeutics
Developing magnetic cell delivery platform for advanced therapies.
Shares Biotechnology
Arrakis Bio is developing novel therapeutics for cancer and other diseases using a proprietary gene editing platform.
Shares Gene Editing, Therapeutics
Key facts
- Website
- crisprtx.com
- Headquarters
- Zug, Switzerland
- Founded
- 2013
- Total funding
- $547M (Series B)
- Business model
- B2B
Funding rounds
Tech stack
Detected on crisprtx.com, last scanned 29 Oct 2026. Run your own scan
- Auth
- Okta
- Email provider
- Proofpoint
CRISPR Therapeutics scores 69. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is CRISPR Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for CRISPR Therapeutics is 67 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has CRISPR Therapeutics raised?
CRISPR Therapeutics has raised a total of $547M in funding. The most recent round on record is Series B.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for CRISPR Therapeutics
